GNI GroupGNI Group Ltd.2160東証グロース医薬品FY ending Dec 2024, consolidated, IFRS
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Dec 2018 | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 |
|---|---|---|---|---|---|---|
| Pharmaceutical | N/A | — | — | — | — | 18,3032.0% |
| Medical device | N/A | — | — | — | — | 5,30719.4% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第25期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第24期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第22期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
訂正有価証券報告書－第21期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第20期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 42 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.